Table 2 ARID1A protein expression related to clinical–pathological variables

From: ARID1A loss is prevalent in endometrial hyperplasia with atypia and low-grade endometrioid carcinomas

Variable

ARID1A a

P-value

 

Loss, n (%)

No loss, n (%)

 

Histological subtype

  

0.031

 Endometrioid

84 (19)

352 (81)

 

 Non-endometrioid

10 (10)

89 (90)

0.049b

Clear-cell

4 (21)

15 (79)

 

Serous

1 (2)

43 (97)

 

Carcinosarcoma/undiff

5 (14)

31 (86)

 

Differentiation (endometrioid only) c

  

0.007

 1

26 (14)

166 (87)

 

 2

44 (27)

122 (74)

 

 3

13 (18)

61 (82)

 

Menopausal status

  

0.583

 Pre-/peri-menopausal

13 (20)

52 (80)

 

 Post menopausal

81 (17)

389 (83)

 

Myometrial infiltration d

  

<0.001

 <50%

44 (13)

296 (87)

 

 >50%

48 (25)

145 (75)

 

DNA ploidy e

  

0.002

 Diploid

58 (20)

227 (80)

 

 Aneuploid

4 (5)

72 (95)

 

Age

  

0.005

 Under median (66 years)

64 (22)

231 (78)

 

 Over median (66 years)

30 (13)

210 (88)

 

FIGO

  

0.253

 Stage I–II

75 (17)

373 (83)

 

 Stage III–IV

19 (22)

68 (78)

 
  1. aARID1A loss is defined as score=0; no loss as score=1-9.
  2. bIn the subgroup of the non-endometrioid subtypes.
  3. cFour cases missing.
  4. dTwo cases missing.
  5. e174 cases missing.